Microsoft to lay off 650 people from videogame business: WSJ
Microsoft Corp. (MSFT) is laying off about 650 employees from its videogame business, the Wall Street Journal reported Thursday, citing an email from the head of Microsoft Gaming that it reviewed. Phil Spencer, chief executive of the unit, said no studios will be closed and no game, device or experience will be canceled. The move is the latest by Microsoft to cut costs after its $75 billion acquisition of Activision Blizzard last year. The company already laid off about 1,900 workers from the unit at the beginning of the year and closed three studios in May. The move comes as the global gaming market, which benefited from stay-at-home mandates during the pandemic, has seen slowing demand since 2022 and has recovered only modestly since then. Microsoft's stock was flat premarket but is up 12.5% in the year to date, while the S&P 500 has gained 16.4%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-12-24 0747ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks